SUNWAY(SZ:002469) Tianfeng Securities·2025-10-27 13:13Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [6][18]. Core Views - The company experienced a temporary pressure on performance in Q3 2025, with revenue of 6.92 billion yuan, a year-on-year increase of 3.61%, and a net profit of 0.33 billion yuan, a year-on-year decrease of 46.18%. However, the company is focusing on optimizing its production of cellulose acetate butyrate and aims to quickly bring new capacity for isooctanoic acid (50,000 tons/year) into production, which is expected to contribute to long-term growth [1][4]. - The company has a robust order backlog, with signed but uncompleted orders amounting to approximately 16.41 billion yuan as of Q3 2025, and new engineering orders signed in Q3 totaling 3.73 billion yuan [2][4]. - The company has shown improved cost control, with a period expense ratio of 9.82%, a year-on-year decrease of 1.19 percentage points. The cash flow remains positive, with a net cash flow from operations of 1.19 billion yuan [3][4]. Financial Performance Summary - For the first three quarters of 2025, the company achieved a revenue of 1.941 billion yuan, a year-on-year increase of 14.63%, and a net profit attributable to the parent company of 153 million yuan, a year-on-year increase of 5.14% [1]. - The gross margin for Q3 2025 was 13.85%, down 6.97 percentage points year-on-year, primarily due to declining chemical product prices, such as a 15.58% drop in the average price of octanol [2]. - The company’s projected net profits for 2025-2027 are adjusted to 265 million, 330 million, and 415 million yuan, respectively, with corresponding P/E ratios of 21.47, 17.24, and 13.71 [4][5].